References
- Centers for Disease Control and Prevention (CDC). Summary health statistics: National health interview survey, 2018. 2018 [accessed 2020 Aug 4]. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2018_SHS_Table_A-2.pdf.
- Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:https://doi.org/10.1183/09031936.00202013.
- Scichilone N, Barnes PJ, Battaglia S, Benfante A, Brown R, Canonica GW, Caramori G, Cazzola M, Centanni S, Cianferoni A, et al. The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians. J Clin Med. 2020;9(8):2397. doi:https://doi.org/10.3390/jcm9082397.
- GINA. Global strategy for asthma management and prevention. 2020 [accessed 20 May 2020]. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.
- FDA. Xolair (omalizumab) highlights of prescribing information. 2003 [accessed 10 June 2020]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf.
- FDA. Nucala (mepolizumab) highlights of prescribing information. 2015 [accessed 10 June 2020]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125526s004lbl.pdf.
- FDA. Cinqair (reslizumab) highlights of prescribing information. 2016 [accessed 10 June 2020]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf.
- FDA. Fasenra (benalizumab) highlights of prescribing information. 2017 [accessed 10 June 2020]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf.
- FDA. Dupixent (dupilumab) highlights of prescribing information. 2017 [accessed 10 June 2020]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf.
- Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:https://doi.org/10.1183/13993003.00936-2018.
- Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, et al. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 2019;123(2):222–224.e1. doi:https://doi.org/10.1016/j.anai.2019.04.028.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:https://doi.org/10.1016/S0140-6736(12)60988-X.
- Prazma C, Albers F, Mallett S, Llanos-Ackert J, Yancey S. Mepolizumab improves patient outcomes and reduces exacerbations in severe asthma patients with comorbid upper airways disease. J Allergy Clin Immunol. 2019;143(2):AB94. doi:https://doi.org/10.1016/j.jaci.2018.12.286.
- Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, Greenberg S, Hanania NA. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. doi:https://doi.org/10.1111/all.13302.
- FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi:https://doi.org/10.1016/S2213-2600(17)30344-2.
- Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:https://doi.org/10.1016/S2213-2600(16)30031-5.
- Gelhorn HL, Balantac Z, Ambrose CS, Chung YN, Stone B. Patient and physician preferences for attributes of biologic medications for severe asthma. PPA. 2019;13:1253–1268. doi:https://doi.org/10.2147/PPA.S198953.
- Janson SL, Solari PG, Trzaskoma B, Chen H, Haselkorn T, Zazzali JL. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol. 2015;114(6):516–521. doi:https://doi.org/10.1016/j.anai.2015.04.010.
- Ortega H, Lemiere C, Llanos J-P, Forshag M, Price R, Albers F, Yancey S, Castro M. Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma Clin Immunol. 2019;15:37. doi:https://doi.org/10.1186/s13223-019-0348-z.
- Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072. doi:https://doi.org/10.1185/03007990802457040.
- Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782. doi:https://doi.org/10.1183/13993003.01782-2017.
- Li P, Kavati A, Puckett JT, Jahnke J, Busse P, Hanania NA, Ortiz B, Doshi JA. Omalizumab treatment patterns among patients with asthma in the US Medicare population. J Allergy Clin Immunol Pract. 2020;8(2):507–515.e10. doi:https://doi.org/10.1016/j.jaip.2019.07.011.
- Doroudchi A, Pathria M, Modena BD. Asthma biologics: comparing trial designs, patient cohorts and study results. Ann Allergy Asthma Immunol. 2020;124(1):44–56. doi:https://doi.org/10.1016/j.anai.2019.10.016.
- Caminati M, Senna G, Stefanizzi G, Bellamoli R, Longhi S, Chieco-Bianchi F, Guarnieri G, Tognella S, Olivieri M, Micheletto C, et al. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med. 2016;16(1):128. doi:https://doi.org/10.1186/s12890-016-0290-5.
- Pepper AN, Hanania NA, Humbert M, Casale TB. How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. J Allergy Clin Immunol Pract. 2021;9(3):1081–1088. doi:https://doi.org/10.1016/j.jaip.2020.10.048.
- Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259.
- Pitsios C, Tsoumani M, Bilò MB, Sturm GJ, Rodríguez Del Río P, Gawlik R, Ruëff F, Paraskevopoulos G, Valovirta E, Pfaar O, et al. Contraindications to immunotherapy: a global approach. Clin Transl Allergy. 2019;9(1):45–10. doi:https://doi.org/10.1186/s13601-019-0285-4.